crenolanib-resistant FLT3 mutants

Stable Identifier
R-HSA-9702581
Type
Pathway
Species
Homo sapiens
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this pathway in the Pathway Browser

Crenolanib is a second-generation type I tyrosine kinase inhibitor with activity against FLT3 (reviewed in Daver et al, 2019; Staudt et al, 2018; Larrosa-Garcia and Bauer, 2017). This pathway describes FLT3 mutants that are resistant to crenolanib-mediated inhibition.

Literature References
PubMed ID Title Journal Year
30651634 Targeting FLT3 mutations in AML: review of current knowledge and evidence

Schlenk, RF, Levis, MJ, Daver, N, Russell, NH

Leukemia 2019
28576946 FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions

Baer, MR, Larrosa-Garcia, M

Mol. Cancer Ther. 2017
30332834 Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance

Staudt, D, Murray, HC, Alvaro, F, Dun, MD, Enjeti, AK, McLachlan, T, Verrills, NM

Int J Mol Sci 2018
Participants
Participates
Disease
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Authored
Reviewed
Created
Cite Us!